Shannon Campbell
Förmögenhet: 19 680 $ per 2026-05-31
Förmögenhet: 19 680 $ per 2026-05-31
Shannon Campbell is currently Director at Zentalis Pharmaceuticals, Inc. since 2026 and Independent Director at Black Diamond Therapeutics, Inc. since 2024.
Formerly, Ms. Campbell was Chief Commercial Officer & Executive VP at Merus NV from 2022 to 2026 and Vice President & General Manager-Oncology at Bayer HealthCare Pharmaceuticals, Inc. from 2005 to 2017.
Education includes undergraduate studies at Ithaca College.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-04-27 | 8 865 ( 0,02 % ) | 19 680 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2024-04-10 |
| ZENTALIS PHARMACEUTICALS, INC. | Direktör/Styrelseledamot | 2026-05-22 |
| Företag | Position | Slut |
|---|---|---|
| MERUS N.V. | Företagsledare/Principal | 2026-01-01 |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Företagsledare/Principal | 2017-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Ithaca College
Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Merus NV
Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån